Advancing beyond immunosuppression,
Striving towards curing autoimmunity.
The Problem
Antibodies, the cornerstone of the immune system, can sometimes turn against us. Our current tools are limited to non-specific, non-curative, and often harmful immunosuppression.
The Solution
Antigen-drug conjugates (AgDCs) are a novel, non-immunosuppressive, and potentially curative class of biologics for antibody-mediated autoimmune diseases. With superb specificity, AgDCs eliminate only the pathological antibodies and autoreactive B-cells while leaving protective immunity intact.
delivering life-changing solutions to autoimmune patients.
Our Story
Canopy’s foundation was inspired by Natalie, a 26yo Myasthenia Gravis patient who suffered severe complications from her immunosuppressive therapy, the only available treatment for millions of autoimmune patients.
It was founded in 2020 by Dr. Kfir Oved, an accomplished serial bio-entrepreneur with dual education in medicine and immunology, with over $350M raised by his various companies.
With a team of passionate drug hunters and thought leaders, Canopy is building novel, non-immunosuppressive, potentially curative biologics for autoimmunity.
Our Vision
Our vision is to develop best-in-class, non-immunosuppressive, and potentially curative therapies for antibody-mediated autoimmune conditions.
This vision is now feasible due to the convergence of advancements in bio-engineering, clinical design, and economic models, paving the way for highly personalized and potentially curative treatments.